- In January 2025, Humacyte announced plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to support the first-in-human clinical study of its small-diameter acellular tissue-engineered vessel (ATEV) for coronary artery bypass grafting. This initiative aims to provide an alternative to synthetic grafts, potentially improving outcomes in vascular surgeries
- In December 2024, AngioDynamics received FDA clearance for its NanoKnife System for the ablation of prostate tissue. The NanoKnife System utilizes irreversible electroporation (IRE) technology to treat prostate cancer, offering a non-thermal, radiation-free alternative that preserves surrounding nerves and tissues, thereby minimizing side effects
- In October 2024, At Melbourne's Alfred Hospital, a groundbreaking clinical trial successfully treated a burn patient using bioengineered skin developed from the patient's own cells. This innovative approach reduces the need for traditional skin grafts and significantly lowers the risk of infection, marking a significant advancement in burn treatment
- In September 2024, Researchers at the University of Pittsburgh's Center for Transcriptional Medicine explored the use of mRNA technology to rejuvenate damaged organs, particularly focusing on the liver. By delivering specific transcription factors via mRNA, the team aims to reprogram terminally ill livers, potentially reducing the need for organ transplants. Clinical trials are anticipated to commence in 2024
- In August 2024, Professor Sir Magdi Yacoub led a pioneering project in the UK to develop heart valves that grow naturally within the body. Utilizing a scaffold made of microscopic fibers, these valves integrate with the patient's cells and dissolve over time, leaving behind a living valve composed of the patient's tissue. This innovation could revolutionize heart valve treatment, especially for children with congenital heart defects
